ALPHARETTA, Ga., Feb. 20, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2023 results.
"We were very pleased with the overall execution on our transformation initiative last year, which sets the foundation for more profitable growth in 2024 and for reaching our mid-term financial targets in 2025," said Joe Woody, Avanos's chief executive officer. Woody continued, "We believe we are poised to maintain the positive momentum in our Digestive Health portfolio and we are also confident that our strategy for the Pain Management and Recovery business will lead to sustainable growth as we enter 2024."
2023 Financial Highlights
During 2023, we completed a number of important steps in furtherance of the three-year transformation initiative that we initiated in January 2023 (the "Transformation Process"). The Transformation Process is focused on four key priorities: optimizing our commercial organization; transforming our product portfolio; implementing cost management initiatives to enhance operating profitability; and continuing to efficiently deploy capital while maintaining a focused and disciplined approach to M&A.
On October 2, 2023, we completed the sale of substantially all of the assets of our respiratory health (RH) business (the "Divestiture"). This transaction was aimed at accelerating our efforts to focus our portfolio in markets where we believe we are well-positioned to succeed. As a result of the Divestiture, the RH business's operating results are reflected as discontinued operations for all periods presented.
On July 24, 2023, we closed the acquisition of Diros Technology, Inc. ("Diros"). Based in Toronto, Canada, Diros is at the forefront of radiofrequency ablation, or RFA, technology used to treat chronic pain conditions. The addition of Diros' unique RF TridentTM technology is expected to further enhance Avanos' Pain Management and Recovery treatment options and complement our premium COOLIEF* Cooled Radiofrequency product offering. We believe the acquisition of Diros represents a significant addition to our product portfolio.
Fourth Quarter 2023 Operating Results From Continuing Operations
In the fourth quarter of 2023, net sales totaled $173.3 million, a 4.6% decrease compared to the prior year, primarily from lower hyaluronic acid ("HA") portfolio sales, partially offset by favorable foreign currency translation effects.
Gross margin for the fourth quarter was 54.8% compared to 56.7% a year ago. Adjusted gross margin was 58.6% compared to 58.9% in the prior year. Gross profit margin decreased primarily due to product mix, partially offset by favorable currency exchange rates and manufacturing efficiencies.
Selling and general expenses as a percentage of net sales was 43.0% compared to 43.3% in the prior year period, primarily due to non-recurring expenses associated with our ongoing Transformation Process, the Diros acquisition and the Divestiture, as well as compliance costs associated with the EU Medical Device Regulation (the "EU MDR").
Operating profit in the quarter was $11.2 million compared to $16.6 million in the fourth quarter of 2022. On an adjusted basis, operating profit was $27.1 million compared to $29.5 million a year ago.
Adjusted EBITDA for the quarter was $32.1 million compared to $33.7 million in the prior year.
Full-Year 2023 Operating Results From Continuing Operations
Net sales decreased 1.6% to $673.3 million in 2023 primarily due to lower volume in the Pain Management and Recovery portfolio (primarily lower sales of HA pain relief products), partially offset by continued strong demand for Digestive Health products. In addition to volume, 0.3% of favorable pricing was offset by 0.2% of unfavorable foreign currency translation effects.
Gross margin for 2023 was 56.4% compared to 57.6% in 2022. Adjusted gross margin was 59.1%, down from 59.9% last year due primarily to unfavorable product mix, partially offset by improved manufacturing efficiencies.
Selling and general expenses as a percentage of net sales were 49.8% compared to 47.7% in the prior year period, driven by higher selling costs, along with non-recurring expenses associated with our ongoing Transformation Process, the Divestiture and the Diros acquisition, as well as compliance costs associated with the EU MDR.
Operating income in 2023 was $4.2 million compared to $35.5 million in the prior year. On an adjusted basis, operating profit was $79.7 million compared to $73.2 million in 2022.
For the full-year, adjusted EBITDA totaled $98.9 million, compared to $91.2 million in the prior year.
Cash Flow and Balance Sheet
Cash from operations less capital expenditures, or free cash flow, for the fourth quarter of 2023 was an outflow of $3.4 million, compared to an inflow of $28.8 million a year ago. For 2023, free cash flow was $14.6 million, compared to $71.6 million in the prior year.
At year-end 2023, the Company's cash balance was $87.7 million compared to $127.7 million at year-end 2022. Total debt at the end of the fourth quarter totaled $168.0 million, consisting of borrowings of $118.8 million on the Company's term loan facility and $49.2 million on the revolving credit facility.
Discontinued Operations
Net sales from discontinued operations were $7.0 million in the three months ended December 31, 2023, compared to $35.9 million in the three months ended December 31, 2022. Net sales from discontinued operations were $100.9 million in the year ended December 31, 2023, compared to $135.9 million in the year ended December 31, 2022. We recognized a loss on disposal of the RH business, and accordingly, we recorded impairment of $70.8 million against assets in the disposal group, which is included in "(Loss) income from discontinued operations, net of tax."
2024 Outlook
The Company expects 2024 net sales to be between $685 and $705 million, which assumes organic growth between 3% to 6%, excluding the impact of the product portfolio rationalization under the Transformation Process. Adjusted gross profit margins are expected to be between 59.5% and 60.5%, adjusted SG&A as a percentage of revenue is expected to be between 41% and 42%, and adjusted diluted earnings per share are expected to be between $1.30 to $1.45.
Non-GAAP Financial Measures
This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:
These non-GAAP financial measures exclude the following items, as applicable, for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:
The Company provides these non-GAAP financial measures as supplemental information to our GAAP financial measures. Management and the Company's Board of Directors use net sales on a constant currency basis, adjusted net income, adjusted diluted earnings per share, adjusted operating profit, adjusted EBITDA, and free cash flow to (a) evaluate the Company's historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the Company's business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of the Company's ongoing business operations.
Additionally, the Compensation Committee of the Company's Board of Directors will use certain of the non-GAAP financial measures when setting and assessing achievement of incentive compensation goals. These goals are based, in part, on the Company's net sales on a constant currency basis and adjusted EBITDA, which will be determined by excluding certain items that are used in calculating these non-GAAP financial measures.
Our competitors may define these non-GAAP financial measures differently, and as a result, our measure of these non-GAAP financial measures may not be directly comparable to those of other companies. Items excluded from these non-GAAP financial measures are significant components in understanding and assessing financial performance. These non-GAAP financial measures are supplemental measures of operating performance that do not represent, and should not be considered in isolation or as an alternative to, or substitute for, the financial statement data presented in our consolidated financial statements as indicators of financial performance. These non-GAAP financial measures have limitations as analytical tools, and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP results and using these non-GAAP financial measures as supplemental information.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the attached financial tables.
Conference Call Webcast
Avanos Medical, Inc. will host a conference call today at 9 a.m. ET. The conference call can be accessed live over the internet at https://avanos.investorroom.com or via telephone by dialing 877-240-5772 in the United States. A replay of the call will be available at noon ET today by calling 877-344-7529 in the United States and entering passcode 5134094. A webcast of the call will also be archived in the Investors section on the Avanos website.
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical device company focused on delivering clinically superior breakthrough solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit www.avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.
Forward-Looking Statements
This press release contains information that includes or is based on "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "may", "believe", "will", "expect", "project", "estimate", "anticipate", "plan", or "continue" and similar expressions, among others. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; shortages in drugs used in our Surgical Pain and Recovery products or other disruptions in our supply chain; the ongoing conflicts between Russia and Ukraine and in the Middle East; our ability to successfully execute on or achieve the expected benefits of the Transformation Process or our divestiture, acquisition or merger transactions; inflationary pressures; rising interest rates; financial conditions affecting the banking system and the potential threats to solvency of commercial banks; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the impact of investigative and legal proceedings and compliance risks; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; and changes in the competitive environment. Additional information concerning these and other factors that may impact future results is contained in our filings with the U.S. Securities and Exchange Commission, including our most recent Form 10-K and Quarterly Reports on Form 10-Q.
AVANOS MEDICAL, INC. | |||||||
Three Months Ended December 31, | Year Ended December 31, | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Net Sales | $ 173.3 | $ 181.6 | $ 673.3 | $ 684.1 | |||
Cost of products sold | 78.3 | 78.7 | 293.6 | 289.9 | |||
Gross Profit | 95.0 | 102.9 | 379.7 | 394.2 | |||
Research and development expenses | 6.8 | 7.2 | 27.2 | 29.2 | |||
Selling and general expenses | 74.5 | 78.7 | 335.0 | 326.5 | |||
Other expense (income), net | 2.5 | 0.4 | 13.3 | 3.0 | |||
Operating Income | 11.2 | 16.6 | 4.2 | 35.5 | |||
Interest income | 1.0 | 0.7 | 2.9 | 1.2 | |||
Interest expense | (3.3) | (3.0) | (15.0) | (10.0) | |||
Income Before Income Taxes | 8.9 | 14.3 | (7.9) | 26.7 | |||
Income tax benefit (provision) | 2.1 | (4.6) | (2.0) | (5.2) | |||
Income (Loss) from Continuing Operations | 11.0 | 9.7 | (9.9) | 21.5 | |||
(Loss) Income from discontinued operations, net of tax | (0.5) | 7.2 | (51.9) | 29.0 | |||
Net Income (Loss) | $ 10.5 | $ 16.9 | $ (61.8) | $ 50.5 | |||
Interest expense, net | 2.3 | 2.3 | 12.1 | 8.8 | |||
Income tax (provision) benefit | (3.4) | 7.0 | 2.9 | 14.7 | |||
Depreciation and amortization | 11.5 | 13.4 | 46.1 | 47.7 | |||
EBITDA | $ 20.9 | $ 39.6 | $ (0.7) | $ 121.7 | |||
Earnings (Loss) Per Share | |||||||
Basic | |||||||
Continuing operations | $ 0.24 | $ 0.21 | $ (0.21) | $ 0.46 | |||
Discontinued operations | $ (0.01) | $ 0.15 | $ (1.11) | $ 0.62 | |||
Basic (Loss) Earnings Per Share | $ 0.23 | $ 0.36 | $ (1.32) | $ 1.08 | |||
Diluted | |||||||
Continuing operations | $ 0.24 | $ 0.21 | $ (0.21) | $ 0.46 | |||
Discontinued operations | $ (0.01) | $ 0.15 | $ (1.11) | $ 0.61 | |||
Diluted (Loss) Earnings Per Share | $ 0.23 | $ 0.36 | $ (1.32) | $ 1.07 | |||
Common Shares Outstanding | |||||||
Basic | 46.2 | 46.5 | 46.6 | 46.9 | |||
Diluted | 46.6 | 47.0 | 46.6 | 47.3 | |||
AVANOS MEDICAL, INC. | |||||||
Three Months Ended December 31, | Year Ended December 31, | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Net Sales | $ 7.0 | $ 35.9 | $ 100.9 | $ 135.9 | |||
Cost of products sold | 11.0 | 21.9 | 68.8 | 80.1 | |||
Gross Profit | (4.0) | 14.0 | 32.1 | 55.8 | |||
Research and development expenses | — | 0.3 | 0.8 | 1.4 | |||
Selling, general and other expenses | (0.7) | 3.9 | 11.2 | 15.4 | |||
Pretax gain (loss) on classification as discontinued operations | (1.5) | — | 70.8 | — | |||
Other expense, net | — | 0.2 | 0.3 | 0.5 | |||
Operating (loss) income | (1.8) | 9.6 | (51.0) | 38.5 | |||
Income tax benefit (provision) from discontinued operations | 1.3 | (2.4) | (0.9) | (9.5) | |||
(Loss) Income from discontinued operations, net of tax | $ (0.5) | $ 7.2 | $ (51.9) | $ 29.0 | |||
AVANOS MEDICAL, INC. | |||||||||||
Gross Profit | |||||||||||
Three Months Ended December 31, 2023 | Three Months Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ 95.0 | $ (4.0) | $ 91.0 | $ 102.9 | $ 14.0 | $ 116.9 | |||||
Acquisition and integration-related charges | 0.4 | — | 0.4 | — | — | — | |||||
Restructuring and transformation charges | 2.4 | — | 2.4 | — | — | — | |||||
Divestiture related charges | — | 1.4 | 1.4 | — | — | — | |||||
EU MDR Compliance | — | — | — | (0.2) | — | (0.2) | |||||
Intangibles amortization | 3.8 | — | 3.8 | 4.3 | — | 4.3 | |||||
As adjusted non-GAAP | $ 101.6 | $ (2.6) | $ 99.0 | $ 107.0 | $ 14.0 | $ 121.0 | |||||
Gross profit margin, as reported | 54.8 % | (57.1) % | 50.5 % | 56.7 % | 39.0 % | 53.7 % | |||||
Gross profit margin, as adjusted | 58.6 % | (37.1) % | 54.9 % | 58.9 % | 39.0 % | 55.6 % | |||||
Gross Profit | |||||||||||
Year Ended December 31, 2023 | Year Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ 379.7 | $ 32.1 | $ 411.8 | $ 394.2 | $ 55.8 | $ 450.0 | |||||
Acquisition and integration-related charges | 0.4 | — | 0.4 | 1.4 | — | 1.4 | |||||
Restructuring and transformation charges | 3.0 | — | 3.0 | — | — | — | |||||
Divestiture related charges | — | 1.4 | 1.4 | — | — | — | |||||
EU MDR Compliance | — | — | — | — | — | — | |||||
Intangibles amortization | 14.6 | — | 14.6 | 14.4 | — | 14.4 | |||||
As adjusted non-GAAP | $ 397.7 | $ 33.5 | $ 431.2 | $ 410.0 | $ 55.8 | $ 465.8 | |||||
Gross profit margin, as reported | 56.4 % | 31.8 % | 53.2 % | 57.6 % | 41.1 % | 54.9 % | |||||
Gross profit margin, as adjusted | 59.1 % | 33.2 % | 55.7 % | 59.9 % | 41.1 % | 56.8 % | |||||
AVANOS MEDICAL, INC. | |||||||||||
Operating Profit (Loss) | |||||||||||
Three Months Ended December 31, 2023 | Three Months Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ 11.2 | $ (1.8) | $ 9.4 | $ 16.6 | $ 9.6 | $ 26.2 | |||||
Acquisition and integration-related charges | 0.9 | — | 0.9 | 0.4 | — | 0.4 | |||||
Restructuring and transformation charges(a) | 5.2 | — | 5.2 | — | — | — | |||||
Divestiture related charges | 0.9 | — | 0.9 | — | — | — | |||||
Estimated loss on Divestiture | — | (1.5) | (1.5) | — | — | ||||||
EU MDR Compliance(b) | 0.9 | — | 0.9 | 1.5 | — | 1.5 | |||||
Litigation and legal | 1.5 | — | 1.5 | — | — | — | |||||
Other items(c) | — | — | — | 3.8 | — | 3.8 | |||||
Intangibles amortization | 6.5 | — | 6.5 | 7.2 | 0.5 | 7.7 | |||||
As adjusted non-GAAP | $ 27.1 | $ (3.3) | $ 23.8 | $ 29.5 | $ 10.1 | $ 39.6 | |||||
Operating Profit | |||||||||||
Year Ended December 31, 2023 | Year Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ 4.2 | $ (51.0) | $ (46.8) | $ 35.5 | $ 38.5 | $ 74.0 | |||||
Acquisition and integration-related charges | 3.3 | — | 3.3 | 3.4 | — | 3.4 | |||||
Restructuring and transformation charges(a) | 28.2 | — | 28.2 | — | — | — | |||||
Divestiture related charges | 6.0 | 0.8 | 6.8 | — | — | — | |||||
Estimated loss on Divestiture | — | 70.8 | 70.8 | — | — | — | |||||
EU MDR Compliance(b) | 3.7 | — | 3.7 | 6.9 | — | 6.9 | |||||
Litigation and legal | 10.0 | — | 10.0 | — | — | — | |||||
Other items(c) | — | — | — | 3.8 | — | 3.8 | |||||
Intangibles amortization | 24.3 | 0.8 | 25.1 | 23.6 | 2.1 | 25.7 | |||||
As adjusted non-GAAP | $ 79.7 | $ 21.4 | $ 101.1 | $ 73.2 | $ 40.6 | $ 113.8 | |||||
(a) | Expenses incurred for the Transformation Process are included in "Costs of products sold," "Research and development," "Selling and general expenses" and "Other expense, net" on the Condensed Consolidated Income Statements. | |||||
(b) | In the three months ended December 31, 2023 and 2022, EU MDR Compliance related charges are included in "Selling and general expenses" on the Condensed Consolidated Income Statements. In the years ended December 31, 2023 and 2022, EU MDR Compliance related charges are included in "Costs of products sold" and "Selling and general expenses" on the Condensed Consolidated Income Statements. | |||||
(c) | Other items in the three months and year ended December 31, 2022 includes $2.6 million of consulting costs associated with evaluation and overall scope and alternatives for transforming our business and $1.2 million for the impairment of certain assets associated with research and development projects that were cancelled. | |||||
AVANOS MEDICAL, INC. | |||||||||||
Income (Loss) Before Taxes | |||||||||||
Three Months Ended December 31, 2023 | Three Months Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ 8.9 | $ (1.8) | $ 7.1 | $ 14.3 | $ 9.6 | $ 23.9 | |||||
Acquisition and integration-related charges | 0.9 | — | 0.9 | 0.4 | — | 0.4 | |||||
Restructuring and transformation charges | 5.2 | — | 5.2 | — | — | — | |||||
Divestiture related charges | 0.9 | — | 0.9 | — | — | — | |||||
Estimated loss on divestiture | — | (1.5) | (1.5) | — | — | — | |||||
EU MDR Compliance | 0.9 | — | 0.9 | 1.5 | — | 1.5 | |||||
Litigation and legal | 1.5 | — | 1.5 | — | — | — | |||||
Other items | — | — | — | 3.8 | — | 3.8 | |||||
Intangibles amortization | 6.5 | — | 6.5 | 7.2 | 0.5 | 7.7 | |||||
As adjusted non-GAAP | $ 24.8 | $ (3.3) | $ 21.5 | $ 27.2 | $ 10.1 | $ 37.3 | |||||
(Loss) Income Before Taxes | |||||||||||
Year Ended December 31, 2023 | Year Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ (7.9) | $ (51.0) | $ (58.9) | $ 26.7 | $ 38.5 | $ 65.2 | |||||
Acquisition and integration-related charges | 3.3 | — | 3.3 | 3.4 | — | 3.4 | |||||
Restructuring and transformation charges | 28.2 | — | 28.2 | — | — | — | |||||
Divestiture related charges | 6.0 | 0.8 | 6.8 | — | — | — | |||||
Estimated loss on Divestiture | — | 70.8 | 70.8 | — | — | — | |||||
EU MDR Compliance | 3.7 | — | 3.7 | 6.9 | — | 6.9 | |||||
Litigation and legal | 10.0 | — | 10.0 | — | — | — | |||||
Intangibles amortization | 24.3 | 0.8 | 25.1 | 23.6 | 2.1 | 25.7 | |||||
Other items | — | — | — | 3.8 | — | 3.8 | |||||
Loss on extinguishment of debt | — | — | — | 1.1 | — | 1.1 | |||||
As adjusted non-GAAP | $ 67.6 | $ 21.4 | $ 89.0 | $ 65.5 | $ 40.6 | $ 106.1 | |||||
AVANOS MEDICAL, INC. | |||||||||||
Tax Benefit (Provision) | |||||||||||
Three Months Ended December 31, 2023 | Three Months Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ 2.1 | $ 1.3 | $ 3.4 | $ (4.6) | $ (2.4) | $ (7.0) | |||||
Tax effects of adjusting items | (10.3) | — | (10.3) | (1.9) | (0.9) | (2.8) | |||||
Effects of the CARES Act and other | — | — | — | 0.5 | — | 0.5 | |||||
As adjusted non-GAAP | $ (8.2) | $ 1.3 | $ (6.9) | $ (6.0) | $ (3.3) | $ (9.3) | |||||
Effective tax rate, as reported | 23.6 % | 72.2 % | (47.9) % | 32.2 % | (25.0) % | 29.3 % | |||||
Effective tax rate, as adjusted | 33.2 % | 39.4 % | 32.3 % | 22.1 % | (32.7) % | 24.9 % | |||||
Tax Provision | |||||||||||
Year Ended December 31, 2023 | Year Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ (2.0) | $ (0.9) | $ (2.9) | $ (5.2) | $ (9.5) | $ (14.7) | |||||
Tax effects of adjusting items | (17.8) | (4.4) | (22.2) | (9.5) | (0.4) | (9.9) | |||||
Effects of the CARES Act and other | — | — | — | (3.3) | — | (3.3) | |||||
As adjusted non-GAAP | $ (19.8) | $ (5.3) | $ (25.1) | $ (18.0) | $ (9.9) | $ (27.9) | |||||
Effective tax rate, as reported | 25.3 % | 1.8 % | 4.9 % | 19.5 % | 24.7 % | 22.5 % | |||||
Effective tax rate, as adjusted | 29.3 % | 24.8 % | 28.2 % | 27.5 % | 24.4 % | 26.3 % | |||||
AVANOS MEDICAL, INC. | |||||||||||
Net Income (Loss) | |||||||||||
Three Months Ended December 31, 2023 | Three Months Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ 11.0 | $ (0.5) | $ 10.5 | $ 9.7 | $ 7.2 | $ 16.9 | |||||
Acquisition and integration-related charges | 0.9 | — | 0.9 | 0.4 | — | 0.4 | |||||
Restructuring and transformation charges | 5.2 | — | 5.2 | — | — | — | |||||
Divestiture related charges | 0.9 | — | 0.9 | — | — | — | |||||
Estimated loss on divestiture | — | (1.5) | (1.5) | — | — | — | |||||
EU MDR Compliance | 0.9 | — | 0.9 | 1.5 | — | 1.5 | |||||
Litigation and legal | 1.5 | — | 1.5 | — | — | — | |||||
Other items | — | — | — | 3.8 | — | 3.8 | |||||
Intangibles amortization | 6.5 | — | 6.5 | 7.2 | 0.5 | 7.7 | |||||
Tax effects of adjusting items | (10.3) | — | (10.3) | (1.9) | (0.9) | (2.8) | |||||
Tax effects of the CARES Act and other | — | — | — | 0.5 | — | 0.5 | |||||
As adjusted non-GAAP | $ 16.6 | $ (2.0) | $ 14.6 | $ 21.2 | $ 6.8 | $ 28.0 | |||||
Diluted (loss) earnings per share, as reported | $ 0.24 | $ (0.01) | $ 0.23 | $ 0.21 | $ 0.15 | $ 0.36 | |||||
Diluted earnings per share, as adjusted | $ 0.36 | $ (0.04) | $ 0.32 | $ 0.45 | $ 0.15 | $ 0.60 | |||||
Net (Loss) Income | |||||||||||
Year Ended December 31, 2023 | Year Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ (9.9) | $ (51.9) | $ (61.8) | $ 21.5 | $ 29.0 | $ 50.5 | |||||
Acquisition and integration-related charges | 3.3 | — | 3.3 | 3.4 | — | 3.4 | |||||
Restructuring and transformation charges | 28.2 | — | 28.2 | — | — | — | |||||
Divestiture related charges | 6.0 | 0.8 | 6.8 | — | — | — | |||||
Estimated loss on divestiture | — | 70.8 | 70.8 | — | — | — | |||||
EU MDR Compliance | 3.7 | — | 3.7 | 6.9 | — | 6.9 | |||||
Litigation and legal | 10.0 | — | 10.0 | — | — | — | |||||
Other items | — | — | — | 3.8 | — | 3.8 | |||||
Intangibles amortization | 24.3 | 0.8 | 25.1 | 23.6 | 2.1 | 25.7 | |||||
Loss on extinguishment of debt | — | — | — | 1.1 | — | 1.1 | |||||
Tax effects of adjusting items | (17.8) | (4.4) | (22.2) | (9.5) | (0.4) | (9.9) | |||||
Tax effects of the CARES Act and other | — | — | — | (3.3) | — | (3.3) | |||||
As adjusted non-GAAP | $ 47.8 | $ 16.1 | $ 63.9 | $ 47.5 | $ 30.7 | $ 78.2 | |||||
Diluted (loss) earnings per share, as reported | $ (0.21) | $ (1.11) | $ (1.32) | $ 0.46 | $ 0.61 | $ 1.07 | |||||
Diluted earnings per share, as adjusted | $ 1.03 | $ 0.35 | $ 1.38 | $ 1.00 | $ 0.65 | $ 1.65 | |||||
AVANOS MEDICAL, INC. | |||||||||||
Selling, General and Administrative Expenses | |||||||||||
Three Months Ended December 31, 2023 | Three Months Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ 74.5 | $ (0.7) | $ 73.8 | $ 78.7 | $ 3.9 | $ 82.6 | |||||
Acquisition and integration-related charges | (0.5) | — | (0.5) | (0.4) | — | (0.4) | |||||
Restructuring and transformation charges | (2.0) | — | (2.0) | — | — | — | |||||
Divestiture related charges | (0.9) | 0.8 | (0.1) | — | — | — | |||||
EU MDR Compliance | (0.9) | — | (0.9) | (1.7) | — | (1.7) | |||||
Other items | — | — | (2.7) | — | (2.7) | ||||||
Intangibles amortization | (2.7) | — | (2.7) | (2.8) | (0.5) | (3.3) | |||||
As adjusted non-GAAP | $ 67.5 | $ 0.1 | $ 67.6 | $ 71.1 | $ 3.4 | $ 74.5 | |||||
SG&A as a percentage of revenue, as reported | 43.0 % | (10.0) % | 40.9 % | 43.3 % | 10.9 % | 38.0 % | |||||
SG&A as a percentage of revenue, as adjusted | 38.9 % | 1.4 % | 37.5 % | 39.2 % | 9.5 % | 34.2 % | |||||
Selling, General and Administrative Expenses | |||||||||||
Year Ended December 31, 2023 | Year Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
As reported | $ 335.0 | $ 11.2 | $ 346.2 | $ 326.5 | $ 15.4 | $ 341.9 | |||||
Acquisition and integration-related charges | (1.5) | — | (1.5) | (2.0) | — | (2.0) | |||||
Restructuring and transformation charges | (22.5) | — | (22.5) | — | — | — | |||||
Divestiture related charges | (6.0) | — | (6.0) | — | — | — | |||||
EU MDR Compliance | (3.7) | — | (3.7) | (7.0) | — | (7.0) | |||||
Other items | — | — | — | (2.7) | — | (2.7) | |||||
Intangibles amortization | (9.7) | (0.8) | (10.5) | (9.2) | (2.1) | (11.3) | |||||
As adjusted non-GAAP | $ 291.6 | $ 10.4 | $ 302.0 | $ 305.6 | $ 13.3 | $ 318.9 | |||||
SG&A as a percentage of revenue, as reported | 49.8 % | 11.1 % | 44.7 % | 47.7 % | 11.3 % | 41.7 % | |||||
SG&A as a percentage of revenue, as adjusted | 43.3 % | 10.3 % | 39.0 % | 44.7 % | 9.8 % | 38.9 % | |||||
AVANOS MEDICAL, INC. | |||||||||||
EBITDA | |||||||||||
Three Months Ended December 31, 2023 | Three Months Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
Net income (loss) | $ 11.0 | $ (0.5) | $ 10.5 | $ 9.7 | $ 7.2 | $ 16.9 | |||||
Interest expense, net | 2.3 | — | 2.3 | 2.3 | — | 2.3 | |||||
Income tax benefit (provision) | (2.1) | (1.3) | (3.4) | 4.6 | 2.4 | 7.0 | |||||
Depreciation | 5.0 | — | 5.0 | 4.2 | 1.5 | 5.7 | |||||
Amortization | 6.5 | — | 6.5 | 7.2 | 0.5 | 7.7 | |||||
EBITDA | 22.7 | (1.8) | 20.9 | 28.0 | 11.6 | 39.6 | |||||
Acquisition and integration-related charges | 0.9 | — | 0.9 | 0.4 | — | 0.4 | |||||
Restructuring and transformation charges | 5.2 | — | 5.2 | — | — | — | |||||
Divestiture related charges | 0.9 | — | 0.9 | — | — | — | |||||
Estimated loss on divestiture | — | (1.5) | (1.5) | — | — | — | |||||
EU MDR Compliance | 0.9 | — | 0.9 | 1.5 | — | 1.5 | |||||
Other items | — | — | — | 3.8 | — | 3.8 | |||||
Litigation and legal | 1.5 | — | 1.5 | — | — | — | |||||
Adjusted EBITDA | $ 32.1 | $ (3.3) | $ 28.8 | $ 33.7 | $ 11.6 | $ 45.3 | |||||
EBITDA | |||||||||||
Year Ended December 31, 2023 | Year Ended December 31, 2022 | ||||||||||
Continuing | Disc. Operations | Total | Continuing | Disc. Operations | Total | ||||||
Net (loss) income | $ (9.9) | $ (51.9) | $ (61.8) | $ 21.5 | $ 29.0 | $ 50.5 | |||||
Interest expense, net | 12.1 | — | 12.1 | 8.8 | — | 8.8 | |||||
Income tax benefit (provision) | 2.0 | 0.9 | 2.9 | 5.2 | 9.5 | 14.7 | |||||
Depreciation | 19.2 | 1.8 | 21.0 | 18.0 | 4.0 | 22.0 | |||||
Amortization | 24.3 | 0.8 | 25.1 | 23.6 | 2.1 | 25.7 | |||||
EBITDA | 47.7 | (48.4) | (0.7) | 77.1 | 44.6 | 121.7 | |||||
Acquisition and integration-related charges | 3.3 | — | 3.3 | 3.4 | — | 3.4 | |||||
Restructuring and transformation charges | 28.2 | — | 28.2 | — | — | — | |||||
Divestiture related charges | 6.0 | 0.8 | 6.8 | — | — | — | |||||
Estimated loss on divestiture | — | 70.8 | 70.8 | — | — | — | |||||
EU MDR Compliance | 3.7 | — | 3.7 | 6.9 | — | 6.9 | |||||
Other items | — | — | — | 3.8 | — | 3.8 | |||||
Litigation and legal | 10.0 | — | 10.0 | — | — | — | |||||
Adjusted EBITDA | $ 98.9 | $ 23.2 | $ 122.1 | $ 91.2 | $ 44.6 | $ 135.8 | |||||
AVANOS MEDICAL, INC. | |||||||
Free Cash Flow | |||||||
Three Months Ended December 31, | Year Ended December 31, | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Cash provided by operating activities | $ 2.5 | $ 33.7 | $ 32.4 | $ 90.9 | |||
Capital expenditures | (5.9) | (4.9) | (17.8) | (19.3) | |||
Free Cash Flow | $ (3.4) | $ 28.8 | $ 14.6 | $ 71.6 | |||
2024 OUTLOOK | |||
Estimated Range | |||
Diluted earnings per share (GAAP) | $ 0.63 | to | $ 0.87 |
Intangibles amortization | 0.37 | to | 0.34 |
Restructuring and transformation charges | 0.08 | to | 0.06 |
Divestiture related charges | 0.12 | to | 0.10 |
Other | 0.10 | to | 0.08 |
Adjusted diluted earnings per share (non-GAAP) | $ 1.30 | to | $ 1.45 |
AVANOS MEDICAL, INC. | |||
As of December 31, | |||
2023 | 2022 | ||
ASSETS | |||
Current Assets | |||
Cash and cash equivalents | $ 87.7 | $ 127.7 | |
Accounts receivable, net of allowances | 142.8 | 167.9 | |
Inventories | 163.2 | 132.3 | |
Prepaid expenses and other current assets | 28.8 | 13.9 | |
Assets held for sale | 64.5 | 182.3 | |
Total Current Assets | 487.0 | 624.1 | |
Property, Plant and Equipment, net | 117.2 | 118.6 | |
Operating Lease Right of Use Assets | 26.8 | 27.5 | |
Goodwill | 796.1 | 760.3 | |
Other Intangible Assets, net | 239.5 | 234.2 | |
Deferred Tax Assets | 6.5 | 4.6 | |
Other Assets | 19.3 | 17.6 | |
TOTAL ASSETS | $ 1,692.4 | $ 1,786.9 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |||
Current Liabilities | |||
Current portion of long-term debt | $ 8.6 | $ 6.2 | |
Current portion of operating lease obligation | 12.8 | 12.0 | |
Trade accounts payable | 56.3 | 67.9 | |
Accrued expenses | 93.2 | 97.8 | |
Liabilities held for sale | 63.7 | 7.1 | |
Total Current Liabilities | 234.6 | 191.0 | |
Long-Term Debt | 159.4 | 226.3 | |
Operating Lease Obligation | 28.3 | 32.5 | |
Deferred Tax Liabilities | 23.8 | 25.4 | |
Other Long-Term Liabilities | 10.0 | 20.5 | |
TOTAL LIABILITIES | 456.1 | 495.7 | |
Stockholders' Equity | 1,236.3 | 1,291.2 | |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 1,692.4 | $ 1,786.9 | |
AVANOS MEDICAL, INC. | |||||||
Three Months Ended December 31, | Year Ended December 31, | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Operating Activities | |||||||
Net income (loss) | $ 10.5 | $ 16.9 | $ (61.8) | $ 50.5 | |||
Depreciation and amortization | 11.5 | 13.4 | 46.1 | 47.7 | |||
Loss on RH disposal | (1.4) | — | 70.8 | — | |||
Net loss on asset dispositions | 0.8 | 1.1 | 1.9 | 1.1 | |||
Changes in operating assets and liabilities | (3.0) | (1.6) | (18.0) | (24.3) | |||
Deferred income taxes and other | (15.9) | 3.9 | (6.6) | 15.9 | |||
Cash Provided by Operating Activities | 2.5 | 33.7 | 32.4 | 90.9 | |||
Investing Activities | |||||||
Capital expenditures | (5.9) | (4.9) | (17.8) | (19.3) | |||
Proceeds from the RH divestiture | 89.0 | — | 89.0 | — | |||
Acquisition of assets and investments in businesses | (2.1) | — | (49.6) | (116.1) | |||
Cash Provided by Used in Investing Activities | 81.0 | (4.9) | 21.6 | (135.4) | |||
Financing Activities | |||||||
Proceeds from issuance of secured debt | — | — | — | 250.0 | |||
Secured debt repayments | (1.6) | (1.6) | (4.7) | (126.6) | |||
Revolving credit facility proceeds | — | — | 55.0 | 150.0 | |||
Revolving credit facility repayments | (95.0) | (20.0) | (115.0) | (170.0) | |||
Purchase of treasury stock | (6.2) | (0.4) | (19.1) | (45.5) | |||
Payment of debt issuance costs | — | — | — | (2.9) | |||
Proceeds from the exercise of stock options | (0.2) | 0.1 | 1.3 | 1.7 | |||
Payment of contingent consideration liabilities | (1.5) | — | (11.7) | — | |||
Cash (Used in) Provided by Financing Activities | (104.5) | (21.9) | (94.2) | 56.7 | |||
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1.6 | 3.8 | 0.2 | (3.0) | |||
Increase in Cash and Cash Equivalents | (19.4) | 10.7 | (40.0) | 9.2 | |||
Cash and Cash Equivalents - Beginning of Period | 107.1 | 117.0 | 127.7 | 118.5 | |||
Cash and Cash Equivalents - End of Period | $ 87.7 | $ 127.7 | $ 87.7 | $ 127.7 | |||
AVANOS MEDICAL, INC. | |||||||||||
Three Months Ended December 31, | Year Ended December 31, | ||||||||||
2023 | 2022 | Change | 2023 | 2022 | Change | ||||||
Digestive health | $ 94.8 | $ 92.9 | 2.0 % | $ 371.6 | $ 340.4 | 9.2 % | |||||
Pain Management and Recovery: | |||||||||||
Surgical pain and recovery | 35.6 | 41.3 | (13.8) % | 139.2 | 160.1 | (13.1) % | |||||
Interventional pain | 42.9 | 47.4 | (9.5) % | 162.5 | 183.6 | (11.5) % | |||||
Total Pain Management and recovery | 78.5 | 88.7 | (11.5) % | 301.7 | 343.7 | (12.2) % | |||||
Total Net Sales | $ 173.3 | $ 181.6 | (4.6) % | $ 673.3 | $ 684.1 | (1.6) % | |||||
Total | Volume | Pricing/Mix | Currency | Other | |||||||
Net Sales - percentage change - QTD | (4.6) % | (4.3) % | (0.8) % | 0.5 % | — % | ||||||
Net Sales - percentage change - YTD | (1.6) % | (1.7) % | 0.3 % | (0.2) % | — % | ||||||
| Last Trade: | US$18.68 |
| Daily Change: | -0.47 -2.45 |
| Daily Volume: | 170,487 |
| Market Cap: | US$858.350M |
November 12, 2024 November 08, 2024 September 09, 2024 July 31, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
